Physician profile
Daoud Abbas Faraj
NPI 1649213463
$5,763.75
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,805 · 2020: $1,262 · 2021: $2,082 · 2022: $161 · 2023: $440 · 2024: $14.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $454.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,913.21 | 2019-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $460.93 | 2019-2023 | Ozempic, Rybelsus |
| Amgen INC. | $448.42 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $396.75 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $271.00 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $258.75 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $248.08 | 2019-2023 | Xifaxan |
| Lilly USA, LLC | $246.46 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $167.62 | 2019-2021 | |
| Corcept Therapeutics | $156.72 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $145.70 | 2021-2023 | |
| Pfizer INC. | $137.17 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.88 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $122.86 | 2019 | |
| Janssen Pharmaceuticals, INC | $86.20 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $82.02 | 2019-2021 | |
| Abbvie INC. | $65.99 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $57.10 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $49.22 | 2019-2020 | |
| Allergan, INC. | $41.99 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $39.03 | 2020-2021 | |
| Indivior INC. | $33.80 | 2019 | |
| Pharming Healthcare, INC. | $29.66 | 2019 | |
| Genentech USA, INC. | $29.39 | 2019 | |
| Redhill Biopharma INC. | $29.28 | 2020 | |
| Shire North American Group INC | $19.32 | 2019 | |
| Daiichi Sankyo INC. | $18.22 | 2020 | |
| Metuchen Pharmaceuticals | $15.20 | 2019 | |
| Concordia Pharmaceuticals INC. | $15.09 | 2019 | |
| Boston Scientific Corporation | $14.57 | 2024 | |
| Zogenix INC. | $12.60 | 2021 | |
| Dexcom, INC. | $12.27 | 2021 | |
| Greer Laboratories, INC. | $12.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daoud Faraj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.